Actelion's ponesimod successful in mid-stage trial in patients with plaque psoriasis
Ponesimod to proceed to Phase III clinical development in psoriasis
21-Dec-2012 -
Actelion announced that its selective S1P1 modulator, ponesimod, successfully met the primary endpoint - the proportion of patients with at least 75% improvement in Psoriasis Area and Severity Index (PASI) from baseline (PASI75) at week 16 - in a double blind, placebo-controlled study conducted ...
Actelion
phase III studies
Ponesimod
+1